LXRX - Lexicon Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Lexicon Pharmaceuticals, Inc.

8800 Technology Forest Place
The Woodlands, TX 77381
United States
281-863-3000
http://www.lexpharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees174

Key Executives

NameTitlePayExercisedYear Born
Mr. Lonnel CoatsPres, CEO & Director1.05MN/A1965
Mr. Jeffrey L. WadeExec. VP of Corp. & Admin. Affairs and CFO610.38kN/A1965
Dr. Pablo LapuertaExec. VP & Chief Medical Officer541.51kN/A1963
Dr. Praveen TyleExec. VP of R&D487.38kN/A1960
Mr. Alexander A. SantiniExec. VP & Chief Commercial OfficerN/AN/A1959
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 clinical development for the treatment of diabetes; and LX9211 that is in Phase 1 clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

Corporate Governance

Lexicon Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.